Joel Isaacson & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Joel Isaacson & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$226K	Buy	506 +14	+3%	+$6.53K	0.01%	413
2025 Q4	$223K	Buy	+492	New	+$212K	0.01%	419
2025 Q3	–	Sell	-454	Closed	-$202K	–	455
2025 Q2	$202K	Hold	454	–	–	0.01%	401
2025 Q1	$220K	Buy	+454	New	+$212K	0.01%	362
2024 Q3	–	Sell	-469	Closed	-$220K	–	379
2024 Q2	$220K	Buy	+469	New	+$204K	0.01%	317
2015 Q3	–	Sell	-1,150	Closed	-$142K	–	777
2015 Q2	$142K	Hold	1,150	–	–	0.04%	210
2015 Q1	$136K	Hold	1,150	–	–	0.03%	215
2014 Q4	$137K	Buy	+1,150	New	+$130K	0.04%	197

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Joel Isaacson & Co's VRTX Position: Q1 2026 in Review

Joel Isaacson & Co increased its Vertex Pharmaceuticals (VRTX) stake by 2.8% in Q1 2026, buying an estimated $6.53K and bringing the position to 506 shares worth $226K. The position accounts for 0.01% of the portfolio, ranked #413.

Joel Isaacson & Co first reported a position in VRTX in Q4 2014 and has held it in 8 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Joel Isaacson & Co held 506 shares of Vertex Pharmaceuticals worth $226K as of Q1 2026.
Joel Isaacson & Co bought 14 Vertex Pharmaceuticals shares in Q1 2026, an estimated $6.53K.
Vertex Pharmaceuticals made up 0.01% of Joel Isaacson & Co's portfolio in Q1 2026, its #413 holding.
Joel Isaacson & Co first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 8 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Joel Isaacson & Co's 13F filing for Q1 2026, filed 23 Apr 2026.